New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
14:14 EDTMKGAY, PFEEMD Serono announces FDA approval of Rebif Rebidose
EMD Serono, a subsidiary of Merck KGaA (MKGAY) and Pfizer (PFE), announced earlier today that the FDA approved Rebif Rebidose, a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis. Rebif Rebidose was designed with the objective to assist with ease of use and to offer patients an alternative delivery option. Rebif Rebidose will be available in a monthly pack in two different doses, 22 micrograms and 44 micrograms, and in a titration pack. Rebif Rebidose will be available in the U.S. in early 2013.
News For MKGAY;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 23, 2014
13:44 EDTPFEISI Group to hold a webinar
Subscribe for More Information
12:11 EDTPFEOn The Fly: Midday Wrap
Stocks on Wall Street were mixed and little changed at midday, amid new rules from the Obama administration on tax inversions and manufacturing data from around the globe. ECONOMIC EVENTS: In the U.S., the FHFA's home price index rose 0.1% in July to 212.7, missing expectations for a rise of 0.5%. Markit's preliminary manufacturing Purchasing Managers' Index for September came in at 57.9, slightly below the consensus forecast for a 58.0 reading. The Richmond Fed manufacturing index for September rose to 14, beating expectations for it to have dropped two points to 10. In China, HSBC's flash manufacturing Purchasing Managers' Index rose to 50.5 from a final reading of 50.2 in August, better than expectations. In Europe, Markit's composite flash PMI for the eurozone dipped to a nine-month low of 52.3, missing expectations for it to hold steady at the 52.5 seen in August. COMPANY NEWS: Shares of several companies, including a number in the pharmaceutical industry, are lower in early trading after the Treasury Department announced new regulations yesterday night that aim to make it tougher for U.S. companies to lower their tax burdens via mergers with foreign companies, otherwise known as "inversions." Among the stocks that moved lower after the new rules were announced was Astrazeneca (AZN), which had previously been a target of Pfizer (PFE) and fell about 4% near midday. Also lower were shares of both Shire (SHPG), which fell 2%, and Abbvie (ABBV), which dropped 1.6%, as the two have previously agreed to merge in a tax inversion deal. Medtronic (MDT) and Covidien (COV), which similarly agreed to an inversion merger, were down 3.3% and 2.7%, respectively. MAJOR MOVERS: Among the notable gainers was Salix Pharmaceuticals (SLXP), which rose more than 5% after The Wall Street Journal reported that Allergan (AGN) is in advanced talks on a deal to buy the company. Shares of Allergan were also up nearly 3% near midday, as the Journal also reported that Allergan rejected a recent buyout offer from Actavis (ACT). Among the noteworthy losers was Ascena Retail (ASNA), which dropped 16% after the apparel retailer's fourth quarter results and fiscal 2015 profit outlook trailed analysts' consensus estimates. Also lower following its own earnings report was auto retailer CarMax (KMX), which fell over 9%. INDEXES: Near midday, the Dow was down 32.91, or 0.19%, to 17,139.77, the Nasdaq was up 2.90, or 0.06%, to 4,530.59, and the S&P 500 was down 2.29, or 0.11%, to 1,992.00.
10:54 EDTPFEStocks, analysts react to Treasury inversion crackdown
Subscribe for More Information
06:40 EDTPFEPiper says don't dismiss potential Pfizer bid for Actavis
Piper Jaffray says it would not be dismissive of Pfizer (PFE) as a potential acquirer of Actavis (ACT). Piper believes Pfizer's public M&A comments are supportive of Actavis' exposure to complex generics and emerging markets. The firm views Actavis shares as attractively valued, irrespective of the acquisition chatter. It reiterates an Overweight rating on the stock with a $280 price target.
September 22, 2014
16:18 EDTMKGAYOn The Fly: Closing Wrap
Subscribe for More Information
12:16 EDTMKGAYOn The Fly: Midday Wrap
Subscribe for More Information
09:41 EDTMKGAYMerck KGaA expects moderate downgrade due to purchase price for Sigma-Aldrich
Subscribe for More Information
09:31 EDTMKGAYMerck KGaA says dividend increase possible following Sigma-Aldrich acquisition
Subscribe for More Information
09:28 EDTMKGAYMerck KGaA says too early to know split of retained, reinvested cost savings
Subscribe for More Information
09:23 EDTMKGAYMerck KGaA: Sigma-Aldrich acquisition is not a tax inversion deal
Subscribe for More Information
09:19 EDTMKGAYMerck KGaA: Sigma-Aldrich deal is quantum leap for life sciences business
Subscribe for More Information
09:15 EDTMKGAYOn The Fly: Pre-market Movers
HIGHER: Sigma-Aldrich (SIAL), up 34% after Merck KGaA (MKGAY) to acquire the company for $17B... Viasystems (VIAS), up 44% after TTM Technologies (TTMI) acquires the company for $16.46 per share in cash and stock. TTM is up 15.5% after the deal... Clorox (CLX), up 5.4% after the New York Post said the company turned down offer to sell or merge with rival... EMC (EMC), up 2.5% after The Wall Street Journal said the company is considering options that could include merging with a rival and held on-and-off merger talks with Hewlett-Packard (HPQ) for almost a year, though the Journal added that those talks recently ended... Epiq Systems (EPIQ), up 9.9% after P2 Capital confirms 16.9% stake in Epiq and that the company turned down the shareholders' $20 per share takeover offer... Dresser-Rand (DRC), up 2.7% after the company sells to Siemens (SIEGY) for $83 per share or $7.6B... TAT Technologies (TATT), up 6.6% after a division of the company signed a maintenance agreement with Republic Airways (RJET). LOWER: Yahoo (YHOO), down 2.1% after stock was downgraded at Bank of America Merrill Lynch and at Bernstein... InvenSense (INVN), down 2.9% after downgraded at RW Baird... Threshold Pharmaceuticals (THLD), down 5.6% after TH-302 Phase 3 trial events to occur later than expected.
06:52 EDTMKGAYSigma-Aldrich volatility expected to move on Merck KGaA acquiring for $17B
Subscribe for More Information
06:06 EDTMKGAYMerck KGaA says transaction approved by Sigma-Aldrich's board of directors
The transaction has been unanimously approved by Sigma - Aldrich’s Board of Directors. A merger agreement will be presented to Sigma - Aldrich shareholders for approval at a special meeting of shareholders. The transactio n has the full support of Merck KGaA, Darmstadt, Germany ’s Executive Board and E. Merck KG including its Board of Partners, and a Merck KGaA, Darmstadt, Germany,shareholder vote will not be required. Closing is expected in mid- year 2015, subject to regulatory approvals and other customary closing conditions. Guggenheim Securities and J.P. Morgan are acting as financial advisers to Merck KGaA, Darmstadt, Germany . Skadden , Arps, Slate, Meagher & Flom LLP is acting as legal adviser to Merck KGaA, Darmstadt, Germany . Morgan Stanley & Co. LLC is acting as financial adviser to Sigma -Aldrich and Sidley Austin LLP is acting as legal adviser.
06:01 EDTMKGAYMerck KGaA to acquire Sigma-Aldrich for $17B
Subscribe for More Information
06:00 EDTMKGAYMerck KGaA to acquire Sigma-Aldrich for $17B
Subscribe for More Information
September 19, 2014
16:00 EDTPFEOptions Update; September 19, 2014
Subscribe for More Information
10:07 EDTPFEHigh option volume stocks
Subscribe for More Information
September 18, 2014
06:21 EDTMKGAYMerck KGaA names Stefan Oschmann as deputy CEO
Subscribe for More Information
September 17, 2014
07:43 EDTPFEBofA/Merrill to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use